Market Segmentation:
- By Therapy Type
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- Glucagon-Like Peptide-1 (GLP-1) Agonists
- Diuretics
- Others (Mineralocorticoid Receptor Antagonists, Dual RAAS Inhibitors, etc.)
- By Drug Class
- Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors
- Antidiabetic Drugs
- Antiproteinuric Agents
- Diuretics
- Others (Immunosuppressants, Anticoagulants, etc.)
- Antihypertensive Agents
- Others (Erythropoiesis-Stimulating Agents, Calcium Channel Blockers, etc.)
- By Route of Administration
- Oral
- Injectable
- Others (Topical, Transdermal, etc.)
- By Distribution Channel
- Hospitals
- Retail Pharmacies
- Online Pharmacies
- Others (Long-term Care Facilities, Specialty Clinics, etc.)
- By End-User
- Hospitals and Clinics
- Dialysis Centers
- Home Care Settings
- Others (Long-term Care Facilities, Research Institutes, etc.)
Frequently Asked Questions
The current market size of the Diabetic Kidney Disease (DKD) industry is USD 7,210 million.
The rising prevalence of diabetes, increasing awareness of DKD, advancements in diagnostics, and the growing demand for effective treatments are the key factors contributing significantly to the growth of the Diabetic Kidney Disease (DKD) market.
The key factors hampering the growth of the Diabetic Kidney Disease (DKD) Market include the side effects of DKD medications, high cost of treatments, limited access to healthcare in some regions, and lack of awareness about DKD in certain populations.
The leading component segment in the Diabetic Kidney Disease (DKD) Market is the SGLT2 Inhibitors, which have shown promising results in delaying the progression of DKD.
The major players operating in the Diabetic Kidney Disease (DKD) Market include Novo Nordisk A/S, Bayer AG, AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Company, Limited.
The Diabetic Kidney Disease (DKD) Market is expected to grow at a CAGR of 7.8% from 2023 to 2031, with a market size of USD 13,148.8 million by 2031.
The key drivers of the Diabetic Kidney Disease (DKD) Market include the rising prevalence of diabetes, increasing awareness of DKD, advancements in diagnostic tools, growing demand for effective treatments, and the focus on early intervention.